Health and Healthcare

Gilead Sciences : GILD

All Gilead Sciences Articles

732 Articles

Chris Lange | Jan 13, 2016 at 8:35 AM EST

Short Interest Remains Mixed for Major Biotechs

The short interest data are out for the December 31 settlement date. 24/7 Wall St. has reviewed the top biotech…

Trey Thoelcke | Jan 8, 2016 at 7:20 AM EST

4 Pharmaceutical Stocks With Big Catalysts Pending in 2016

This is going to be a big year in biotech, with a host of drugs set to undergo FDA scrutiny.…

Jon C. Ogg | Jan 6, 2016 at 8:40 AM EST

Top Analyst Upgrades and Downgrades: Bluebird Bio, Check Point, Comcast, Eli Lilly, Hyatt, Lockheed Martin, Rite Aid and Many More

The top analyst calls for Wednesday, January 6, 2016, include Bluebird Bio, Check Point Software, Comcast, Eli Lilly, Hyatt Hotels,…

Chris Lange | Dec 29, 2015 at 11:15 AM EST

5 of the Cheapest Value Stocks for 2016 From the S&P 500

24/7 Wall St. is taking a look at the bottom line for companies in the S&P 500 going into 2016,…

Chris Lange | Dec 28, 2015 at 8:40 AM EST

Short Interest Remains Mixed in Major Biotechs

The short interest data are out for the December 15 settlement date, and short interest continued to be mixed in…

Jon C. Ogg | Dec 21, 2015 at 4:35 PM EST

Are Record Stock Buybacks Putting in a Stock Market Floor?

New data suggests that the stock market's performance in 2015 was bolstered or supported by the largest S&P 500 companies…

Jon C. Ogg | Dec 15, 2015 at 4:52 PM EST

How Amgen’s Larger-Than-Expected Dividend Hike Stacks Up to Peers

Amgen is getting aggressive enough on its dividend payout that you might think the biotech giant is now just a…

Paul Ausick | Dec 10, 2015 at 1:10 PM EST

Apple, Google, Tesla Are World’s Most Innovative Companies

Over the past 10 years the single, most innovative company in the world has been Apple, according to the Boston…

Chris Lange | Dec 10, 2015 at 8:40 AM EST

Mixed Views on Major Biotech Short Interest

The November 30 short interest data have been compared with the previous report, and short interest was mixed in these…

Chris Lange | Nov 25, 2015 at 9:06 AM EST

Short Sellers Run for Cover From Major Biotechs

24/7 Wall St. has reviewed the short interest data on the top biotech companies.

Douglas A. McIntyre | Nov 23, 2015 at 10:28 AM EST

10 Stocks to Pick Up in December

Here are 10 stocks that could outperform the index funds from now to early February.

Chris Lange | Nov 16, 2015 at 10:35 AM EST

Merck Prepares to Break Into HCV Market With Recent Study Results

Merck is joining the likes of Gilead Sciences in producing hepatitis C vaccines, but it is still in the early…

Chris Lange | Nov 11, 2015 at 7:45 AM EST

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the October 30 settlement date, and short interest fell in selected biotech stocks.

Chris Lange | Nov 1, 2015 at 9:10 AM EST

4 Key FDA Decisions Expected in November and December

24/7 Wall St. has collected several big FDA decisions coming up in the month of November.

Chris Lange | Oct 27, 2015 at 4:22 PM EDT

Are Gilead Earnings Enough for Investors?

Gilead Sciences reported its third-quarter financial results after the markets closed on Tuesday.

1 … 28 29 30 31 32 … 49

Gilead Sciences : GILD

All Gilead Sciences Articles

Short Interest Remains Mixed for Major Biotechs

4 Pharmaceutical Stocks With Big Catalysts Pending in 2016

Top Analyst Upgrades and Downgrades: Bluebird Bio, Check Point, Comcast, Eli Lilly, Hyatt, Lockheed Martin, Rite Aid and Many More

5 of the Cheapest Value Stocks for 2016 From the S&P 500

Short Interest Remains Mixed in Major Biotechs

Are Record Stock Buybacks Putting in a Stock Market Floor?

How Amgen’s Larger-Than-Expected Dividend Hike Stacks Up to Peers

Apple, Google, Tesla Are World’s Most Innovative Companies

Mixed Views on Major Biotech Short Interest

Short Sellers Run for Cover From Major Biotechs

10 Stocks to Pick Up in December

Merck Prepares to Break Into HCV Market With Recent Study Results

Short Sellers Run for Cover From Major Biotechs

4 Key FDA Decisions Expected in November and December

Are Gilead Earnings Enough for Investors?

‘You’re Gonna Go Into Retirement Broke and Wait on Mom to Die’: Dave Ramsey’s Reality Check for a Caller Eyeing His Inheritance

“You Don’t Want to Pass the Burden of Investments Down to Your Daughter”: Suze Orman’s Advice to a 78-Year-Old With a Disabled Heir and $111K in Savings

EEM’s 0.69% Fee Quietly Costs You $690 a Year, but Your Cheaper Alternative Charges $90

'You're Gonna Go Into Retirement Broke and Wait on Mom to Die': Dave Ramsey's Reality Check for a Caller Eyeing His Inheritance

"You Don't Want to Pass the Burden of Investments Down to Your Daughter": Suze Orman's Advice to a 78-Year-Old With a Disabled Heir and $111K in Savings

‘You’re Gonna Go Into Retirement Broke and Wait on Mom to Die’: Dave Ramsey’s Reality Check for a Caller Eyeing His Inheritance

“You Don’t Want to Pass the Burden of Investments Down to Your Daughter”: Suze Orman’s Advice to a 78-Year-Old With a Disabled Heir and $111K in Savings

Gilead Sciences : GILD

All Gilead Sciences Articles

Short Interest Remains Mixed for Major Biotechs

4 Pharmaceutical Stocks With Big Catalysts Pending in 2016

Top Analyst Upgrades and Downgrades: Bluebird Bio, Check Point, Comcast, Eli Lilly, Hyatt, Lockheed Martin, Rite Aid and Many More

5 of the Cheapest Value Stocks for 2016 From the S&P 500

Short Interest Remains Mixed in Major Biotechs

Are Record Stock Buybacks Putting in a Stock Market Floor?

How Amgen’s Larger-Than-Expected Dividend Hike Stacks Up to Peers

Apple, Google, Tesla Are World’s Most Innovative Companies

Mixed Views on Major Biotech Short Interest

Short Sellers Run for Cover From Major Biotechs

10 Stocks to Pick Up in December

Merck Prepares to Break Into HCV Market With Recent Study Results

Short Sellers Run for Cover From Major Biotechs

4 Key FDA Decisions Expected in November and December

Are Gilead Earnings Enough for Investors?

‘You’re Gonna Go Into Retirement Broke and Wait on Mom to Die’: Dave Ramsey’s Reality Check for a Caller Eyeing His Inheritance

“You Don’t Want to Pass the Burden of Investments Down to Your Daughter”: Suze Orman’s Advice to a 78-Year-Old With a Disabled Heir and $111K in Savings

EEM’s 0.69% Fee Quietly Costs You $690 a Year, but Your Cheaper Alternative Charges $90

Featured Reads

'You're Gonna Go Into Retirement Broke and Wait on Mom to Die': Dave Ramsey's Reality Check for a Caller Eyeing His Inheritance

"You Don't Want to Pass the Burden of Investments Down to Your Daughter": Suze Orman's Advice to a 78-Year-Old With a Disabled Heir and $111K in Savings